Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BBIO NYSE:QGEN NASDAQ:RARE NYSE:RDY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBIOBridgeBio Pharma$51.21-2.6%$48.54$21.72▼$54.60$10.06B1.252.19 million shs2.09 million shsQGENQiagen$45.30-1.7%$48.47$37.63▼$51.88$10.24B0.641.32 million shs992,179 shsRAREUltragenyx Pharmaceutical$30.31-2.9%$29.70$25.81▼$60.37$3.01B0.211.30 million shs1.39 million shsRDYDr. Reddy's Laboratories$14.65-0.5%$14.33$12.26▼$16.19$12.30B0.32760,165 shs904,411 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBIOBridgeBio Pharma0.00%-4.07%+0.06%+28.73%+82.96%QGENQiagen0.00%-4.70%-7.46%-3.77%+1.62%RAREUltragenyx Pharmaceutical0.00%-4.75%+4.48%-19.15%-46.19%RDYDr. Reddy's Laboratories0.00%+2.20%+3.72%-7.27%-7.58%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBIOBridgeBio Pharma$51.21-2.6%$48.54$21.72▼$54.60$10.06B1.252.19 million shs2.09 million shsQGENQiagen$45.30-1.7%$48.47$37.63▼$51.88$10.24B0.641.32 million shs992,179 shsRAREUltragenyx Pharmaceutical$30.31-2.9%$29.70$25.81▼$60.37$3.01B0.211.30 million shs1.39 million shsRDYDr. Reddy's Laboratories$14.65-0.5%$14.33$12.26▼$16.19$12.30B0.32760,165 shs904,411 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBIOBridgeBio Pharma0.00%-4.07%+0.06%+28.73%+82.96%QGENQiagen0.00%-4.70%-7.46%-3.77%+1.62%RAREUltragenyx Pharmaceutical0.00%-4.75%+4.48%-19.15%-46.19%RDYDr. Reddy's Laboratories0.00%+2.20%+3.72%-7.27%-7.58%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBBIOBridgeBio Pharma 3.00Buy$63.9424.86% UpsideQGENQiagen 2.27Hold$49.699.68% UpsideRAREUltragenyx Pharmaceutical 2.92Moderate Buy$81.50168.89% UpsideRDYDr. Reddy's Laboratories 2.80Moderate Buy$16.9515.70% UpsideCurrent Analyst Ratings BreakdownLatest RARE, RDY, QGEN, and BBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/12/2025BBIOBridgeBio PharmaUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$72.00 ➝ $82.009/9/2025RAREUltragenyx PharmaceuticalHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$80.009/5/2025RAREUltragenyx PharmaceuticalCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$105.009/3/2025BBIOBridgeBio PharmaJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$55.00 ➝ $70.008/29/2025BBIOBridgeBio PharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$56.00 ➝ $70.008/15/2025RDYDr. Reddy's LaboratoriesZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold8/8/2025RAREUltragenyx PharmaceuticalCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$136.00 ➝ $128.008/7/2025QGENQiagenCowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold8/7/2025QGENQiagenUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$48.00 ➝ $50.008/6/2025BBIOBridgeBio PharmaScotiabankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Outperform$55.00 ➝ $57.008/6/2025BBIOBridgeBio PharmaOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$60.00 ➝ $61.00(Data available from 9/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBBIOBridgeBio Pharma$235.81M41.52N/AN/A($7.71) per share-6.64QGENQiagen$2.04B4.94$3.15 per share14.37$16.05 per share2.82RAREUltragenyx Pharmaceutical$560.23M5.21N/AN/A$2.76 per share10.98RDYDr. Reddy's Laboratories$3.81B3.21$1.03 per share14.27$4.73 per share3.10Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBBIOBridgeBio Pharma-$535.76M-$4.09N/AN/AN/A-329.25%N/A-85.69%11/11/2025 (Estimated)QGENQiagen$83.59M$1.6926.7618.412.4318.30%14.77%8.87%11/5/2025 (Estimated)RAREUltragenyx Pharmaceutical-$569.18M-$5.53N/AN/AN/A-87.34%-237.48%-37.66%11/4/2025 (Estimated)RDYDr. Reddy's Laboratories$663M$0.6622.2017.875.9516.99%17.25%11.63%11/4/2025 (Estimated)Latest RARE, RDY, QGEN, and BBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025BBIOBridgeBio Pharma-$0.83-$0.95-$0.12-$0.95$98.46 million$110.57 million8/5/2025Q2 2025QGENQiagen$0.60$0.60N/A$0.44$523.97 million$533.54 million8/5/2025Q2 2025RAREUltragenyx Pharmaceutical-$1.27-$1.17+$0.10-$1.17$161.37 million$166.50 million7/23/2025Q1 25/26RDYDr. Reddy's Laboratories$0.18$0.20+$0.02$0.20$88.27 billion$988.82 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBBIOBridgeBio PharmaN/AN/AN/AN/AN/AQGENQiagen$0.250.55%N/A14.79%N/ARAREUltragenyx PharmaceuticalN/AN/AN/AN/AN/ARDYDr. Reddy's Laboratories$0.070.48%N/A10.61%N/ALatest RARE, RDY, QGEN, and BBIO DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date6/30/2025RDYDr. Reddy's Laboratoriesannual$0.09150.623832253665189%7/25/20257/10/20258/6/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBBIOBridgeBio PharmaN/A5.195.08QGENQiagen0.251.611.35RAREUltragenyx PharmaceuticalN/A2.452.30RDYDr. Reddy's Laboratories0.011.891.36Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBBIOBridgeBio Pharma99.85%QGENQiagen70.00%RAREUltragenyx Pharmaceutical97.67%RDYDr. Reddy's Laboratories3.85%Insider OwnershipCompanyInsider OwnershipBBIOBridgeBio Pharma18.20%QGENQiagen9.00%RAREUltragenyx Pharmaceutical5.50%RDYDr. Reddy's Laboratories2.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBBIOBridgeBio Pharma400191.17 million156.38 millionOptionableQGENQiagen5,765222.29 million202.29 millionOptionableRAREUltragenyx Pharmaceutical1,29496.37 million91.07 millionOptionableRDYDr. Reddy's Laboratories27,811834.90 million818.20 millionOptionableRARE, RDY, QGEN, and BBIO HeadlinesRecent News About These CompaniesDr. Reddy’s Laboratories Announces Resignation of CHROSeptember 14 at 5:11 AM | theglobeandmail.comAcadian Asset Management LLC Buys 23,582 Shares of Dr. Reddy's Laboratories Ltd $RDYSeptember 14 at 4:56 AM | marketbeat.comDr. Reddy's Laboratories Ltd $RDY Stock Holdings Lifted by Millennium Management LLCSeptember 10, 2025 | marketbeat.comDr. Reddy’s Laboratories Receives USFDA Observations at UK FacilitySeptember 8, 2025 | msn.comRoyal Bank of Canada Sells 986,447 Shares of Dr. Reddy's Laboratories Ltd $RDYSeptember 5, 2025 | marketbeat.comDr. Reddy's Laboratories Ltd $RDY Shares Sold by Northern Trust CorpSeptember 4, 2025 | marketbeat.comDr. Reddy's Laboratories Ltd $RDY Stake Lowered by OMERS ADMINISTRATION CorpSeptember 2, 2025 | marketbeat.comBNP Paribas Financial Markets Purchases 1,682,363 Shares of Dr. Reddy's Laboratories Ltd $RDYSeptember 2, 2025 | marketbeat.comOLD Mission Capital LLC Has $3.45 Million Stock Position in Dr. Reddy's Laboratories Ltd $RDYSeptember 1, 2025 | marketbeat.comHsbc Holdings PLC Sells 21,500 Shares of Dr. Reddy's Laboratories Ltd $RDYSeptember 1, 2025 | marketbeat.comDr. Reddy's Laboratories Ltd $RDY Shares Acquired by Invesco Ltd.September 1, 2025 | marketbeat.comWellington Management Group LLP Reduces Stock Holdings in Dr. Reddy's Laboratories Ltd $RDYAugust 31, 2025 | marketbeat.comJump Financial LLC Boosts Holdings in Dr. Reddy's Laboratories Ltd $RDYAugust 30, 2025 | marketbeat.comCW Advisors LLC Acquires New Position in Dr. Reddy's Laboratories Ltd $RDYAugust 30, 2025 | marketbeat.comCauseway Capital Management LLC Sells 394,866 Shares of Dr. Reddy's Laboratories Ltd $RDYAugust 28, 2025 | marketbeat.comAmerican Century Companies Inc. Increases Position in Dr. Reddy's Laboratories Ltd $RDYAugust 28, 2025 | marketbeat.comDr. Reddy’s Laboratories Secures Interim Stay on Tax Reassessment OrderAugust 26, 2025 | msn.comVanguard Group Inc. Buys 106,457 Shares of Dr. Reddy's Laboratories Ltd $RDYAugust 26, 2025 | marketbeat.comQuantbot Technologies LP Makes New $1.26 Million Investment in Dr. Reddy's Laboratories Ltd $RDYAugust 25, 2025 | marketbeat.comDeutsche Bank AG Cuts Stock Holdings in Dr. Reddy's Laboratories Ltd $RDYAugust 24, 2025 | marketbeat.comGroupama Asset Managment Buys New Position in Dr. Reddy's Laboratories Ltd $RDYAugust 23, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025MP Materials: How One Move Redefined the U.S. Magnet Supply ChainBy Jeffrey Neal Johnson | August 27, 2025Amazon Faces Rare Downgrade—Is the Rally at Risk?By Sam Quirke | September 2, 2025Energy Fuels: Is This America's Most Strategic Stock?By Jeffrey Neal Johnson | September 6, 2025RARE, RDY, QGEN, and BBIO Company DescriptionsBridgeBio Pharma NASDAQ:BBIO$51.21 -1.39 (-2.64%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$52.71 +1.50 (+2.93%) As of 09/12/2025 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.Qiagen NYSE:QGEN$45.30 -0.76 (-1.65%) Closing price 09/12/2025 03:59 PM EasternExtended Trading$45.29 -0.01 (-0.02%) As of 09/12/2025 05:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.Ultragenyx Pharmaceutical NASDAQ:RARE$30.31 -0.92 (-2.95%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$30.68 +0.37 (+1.20%) As of 09/12/2025 06:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.Dr. Reddy's Laboratories NYSE:RDY$14.65 -0.08 (-0.54%) Closing price 09/12/2025 03:59 PM EasternExtended Trading$14.66 +0.00 (+0.03%) As of 09/12/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
